Maze Therapeutics (MAZE) Cash from Financing Activities (2024 - 2026)

Maze Therapeutics' Cash from Financing Activities history spans 3 years, with the latest figure at $42.4 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 66.75% to $42.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $190.3 million, a 2.72% decrease, with the full-year FY2025 number at $275.3 million, up 196.55% from a year prior.
  • Cash from Financing Activities hit $42.4 million in Q1 2026 for Maze Therapeutics, up from $3.6 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for MAZE hit a ceiling of $143.8 million in Q3 2025 and a floor of -$2.2 million in Q3 2024.
  • Historically, Cash from Financing Activities has averaged $45.6 million across 3 years, with a median of $24.6 million in 2024.
  • The widest YoY moves for Cash from Financing Activities: up 6786.37% in 2025, down 94.89% in 2025.
  • Tracing MAZE's Cash from Financing Activities over 3 years: stood at $70.3 million in 2024, then tumbled by 94.89% to $3.6 million in 2025, then soared by 1079.86% to $42.4 million in 2026.
  • Business Quant data shows Cash from Financing Activities for MAZE at $42.4 million in Q1 2026, $3.6 million in Q4 2025, and $143.8 million in Q3 2025.